

# A patient-centric approach to advance respiratory drug development

Our patient-first point of view helps us shape successful respiratory studies. Learn how our experienced team strives to be more than a partner. Together, we can make your trial more attractive to potential participants and promote increased recruitment and retention rates in today's highly competitive respiratory studies. We're here to help your program succeed. Count on us to provide:

- **Data-driven protocol optimization:** We'll evaluate your protocols and make recommendations for adjusting the eligibility criteria and protocol design to reduce high screen failure rates
- **More efficient data delivery:** We provide recommendations on spirometry and imaging requirements to find the most efficient way to deliver your data
- **A decentralized approach:** By examining the number of procedures and suggesting decentralized clinical trial (DCT) mechanisms that can capture trial data from both the clinic and a remote setting, we can help reduce potential burdens faced by your investigators and patients—and maximize your data collection

Our team of specialists can help advance your therapy at any stage along the drug development continuum. Reach out to learn more about how we can meet your needs.



**Michael George, MD**  
Global Head Development &  
Therapeutic Area Expertise  
[michael.george@fortrea.com](mailto:michael.george@fortrea.com)



**Veerle Van De Velde, MD**  
Senior Medical Director  
Inflammation, Infectious Disease  
and General Medicine  
[veerle.vandavelde@fortrea.com](mailto:veerle.vandavelde@fortrea.com)



**Mark Dowling**  
Senior Director, Strategy and Planning  
Inflammation, Infectious Disease  
and General Medicine  
[mark.dowling@fortrea.com](mailto:mark.dowling@fortrea.com)



**Karina Putineanu, MD**  
Senior Medical Director  
Infectious Diseases and Critical Care  
[annakarina.putineanu@fortrea.com](mailto:annakarina.putineanu@fortrea.com)



**Verena Schnackenberg**  
Senior Director, Strategy and Planning  
Inflammation, Infectious Disease  
and General Medicine  
[verena.schnackenberg@fortrea.com](mailto:verena.schnackenberg@fortrea.com)



**Dunja Mihajlovic, PhD**  
Associate Medical Director  
Inflammation, Infectious Disease and  
General Medicine  
[dunja.mihajlovic@fortrea.com](mailto:dunja.mihajlovic@fortrea.com)



**Ryan Raphael Zantua, MD**  
Medical Director  
Inflammation, Infectious Disease and  
General Medicine  
[raphaelryan.zantua@fortrea.com](mailto:raphaelryan.zantua@fortrea.com)



**Dana Romano, MD**  
Senior Medical Director  
Inflammation, Infectious Disease and  
General Medicine  
[dana.romano@fortrea.com](mailto:dana.romano@fortrea.com)

Your trusted source for delivering respiratory studies


We understand the challenges that respiratory studies face in today’s clinical trial landscape. We can provide you with meaningful insights and design studies based on your needs, drawing from our extensive global experience and expertise in specialized respiratory tests and analyses.

Pulmonary and respiratory experience by indication

Indication	Studies	Sites	Patients
Asthma	42	1,766	7,912
Bronchiolitis Obliterans Syndrome (BOS)	4	84	520
Chronic Obstructive Pulmonary Disease (COPD)	30	2,259	23,691
Cystic Fibrosis	23	924	3,166
Idiopathic Pulmonary Fibrosis (IPF)	34	1,114	3,670
Progressive Pulmonary Fibrosis	2	482	1,900

Pulmonary and respiratory experience by phase

Data presented is ongoing as of Jan 2020-Dec 2024.



We’re inspired to innovate and shape the future for respiratory patients

 **LEARN MORE** at [fortrea.com](https://fortrea.com)